Diabetes Inflammatory markers associated with development of diabetes in people taking HIV therapy

Published: October 20, 2014

aidsmap
Michael Carter
Original Article:  bit.ly/1CNrrxF

Low-level elevations in important markers of systemic inflammation are associated with the development of type-2 diabetes in people taking antiretroviral therapy (ART), investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The authors examined the relationship between baseline levels of high sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) and incident type-2 diabetes among people in two large HIV treatment strategy trials – the SMART and ESPRIT studies. The study participants were taking continuous ART without any adjunct therapy. Higher baseline hsCRP and IL-6 were associated with diagnosis with type-2 diabetes during follow-up.

“Inflammatory markers provide independent information for predicting the development of diabetes,” comment the authors. “Experimental studies aimed at reducing inflammation are needed to establish a causal relationship.”

Improvements in treatment and care mean that many people with HIV now have an excellent life expectancy. However, HIV infection – even in the context of effective ART – is associated with a higher risk of metabolic complications, including the development of type-2 diabetes. The reasons for this are unclear, but possible causes include the side-effects of some anti-HIV drugs and the inflammatory effects of HIV infection, which can persist at low levels even in the context of ART.

Full text of article available at link below:  bit.ly/1CNrrxF

Leave a Reply

Your email address will not be published. Required fields are marked *